Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Last trade$2.87
Day change-$0.15 (-4.97%)
Day range$2.83 – $3.12
Volume186,678
Market cap$305M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$304.57M
Price / earnings
—
Price / book
-2.2×
Price / sales
—
EV / sales
—
EV / EBITDA
-20.76×
Profitability
Earnings per share
-$0.28
Return on assets
-189.04%
Return on equity
20.23%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.24×
Current ratio
0.1×
Quick ratio
0.1×
Cash ratio
0.09×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$15.89M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GALT, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.85M
$1.85M
$1.43M
$1.59M
$1.36M
$1.41M
$1.32M
$1.47M
Research and development
$2.14M
$2.23M
$1.93M
$2.61M
$3.26M
$6.49M
$11.11M
$7.6M
Total operating expenses
$3.98M
$4.08M
$3.37M
$4.2M
$4.63M
$7.9M
$12.43M
$9.07M
Operating income
-$3.98M
-$4.08M
-$3.37M
-$4.2M
-$4.63M
-$7.9M
-$12.43M
-$9.07M
Interest expense
-$2M
-$1.99M
-$1.94M
-$1.82M
-$1.83M
-$1.74M
-$1.73M
-$1.49M
Income before taxes
-$9.11M
-$5.05M
-$5.5M
-$8.18M
-$7.52M
-$9.63M
-$11.97M
-$11.22M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$9.11M
-$5.05M
-$5.5M
-$8.18M
-$7.52M
-$9.63M
-$11.97M
-$11.22M
Net income attributable to common shareholders
-$9.18M
-$5.07M
-$5.56M
-$8.22M
-$7.58M
-$9.61M
-$12.03M
-$11.24M
EBITDA
-$3.98M
-$4.08M
-$3.37M
-$4.2M
-$4.63M
-$7.9M
-$12.43M
-$9.07M
Basic earnings per share
-$0.14
-$0.08
-$0.09
-$0.13
-$0.12
-$0.15
-$0.19
-$0.18
Diluted earnings per share
-$0.14
-$0.08
-$0.09
-$0.13
-$0.12
-$0.15
-$0.19
-$0.18
Recent news
Company coverage with links to the original publishers.
Galectin Therapeutics presented new data from its NAVIGATE trial at EASL 2026 showing that belapectin 2 mg/kg demonstrated statistically significant reduction in new varices development at 18 months (p=0.04) and improvements in liver stiffness in patients with advanced MASH cirrhosis. The poster presentation on portal hypertension risk reduction was designated a TOP Poster at the conference. These findings support belapectin's potential as a disease-modifying therapy, with no currently approved alternatives available for this indication.
Galectin Therapeutics reported Q3 2025 financial results, highlighting promising biomarker data from the NAVIGATE trial for belapectin in treating MASH cirrhosis. The company submitted data to the FDA and is seeking guidance on next steps, with encouraging results showing potential disease progression reduction.
Galectin Therapeutics is hosting a virtual event to discuss its drug belapectin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The event will feature key opinion leaders and highlight results from the company's NAVIGATE Phase 3 clinical trial.
Galectin Therapeutics announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented at the 2025 MASH-TAG Conference. The company's executive leadership will also host one-on-one meetings during the JP Morgan Healthcare Conference to discuss the NAVIGATE topline results and the next steps for the belapectin program.
Galectin Therapeutics reported financial results for Q2 2024, with a net loss of $12.4 million. The company's lead drug, belapectin, is in a Phase 2b/3 trial for the treatment of MASH-related liver cirrhosis, with interim data expected in December 2024.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.